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Letter to the editor 
Dear Prof. Siepmann, 
Please find attached our manuscript entitled “A novel approach to support formulation design on twin 
screw wet granulation technology: Understanding the impact of overarching excipient properties on drug 
product quality attributes” to be considered for publication as a research article in International Journal 
of Pharmaceutics. 
The submitted work is the follow-up study to the paper which was recently published by your journal 
(“Identifying overarching excipient properties towards an in-depth understanding of process and product 
performance for continuous twin screw wet granulation”). This study presents a combination of principal 
component analysis with design of experiments with the objective to understand the impact of excipient 
characteristics on granule and tablet properties produced via continuous twin screw wet granulation. The 
formulation understanding as well as the statistical models can be used to support a lean formulation 
development: to avoid unnecessary experiments, excipients with appropriate characteristics can be 
selected in order to compensate for unfavourable API properties. The predictive power of the model can 
be used for formulation optimization and troubleshooting, by selecting fillers and binders with 
appropriate properties to improve suboptimal granule or tablet characteristics. 
A thorough understanding of the influence of the formulation composition and excipient characteristics 
on both process performance and the drug product’s critical quality attributes is a fundamental part in 
the product design. Thus, we consider this study to be of high relevance, especially for continuous 
manufacturing processes. 
This manuscript is not under consideration at any other journal and has not been rejected in the past by 
any journal. The document has not been published elsewhere in the same form in English or any other 
language. 
We appreciate your support for the publication of this article in International Journal of Pharmaceutics. 
On behalf of all authors, 
 
Nina Willecke 
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Abstract 
The overall objective of this work is to understand how excipient characteristics influence the drug 
product quality attributes and process performance of a continuous twin screw wet granulation process. 
The knowledge gained in this study is intended to be used for Quality by Design (QbD)-based formulation 
design and formulation optimization. Three principal components which represent the overarching 
properties of 8 selected pharmaceutical fillers were used as factors, whereas factors 4 and 5 represented 
binder type and binder concentration in a design of experiments (DoE). The majority of process 
parameters were kept constant to minimize their influence on the granule and drug product quality. 27 
DoE batches consisting of binary filler/binder mixtures were processed via continuous twin screw wet 
granulation followed by tablet compression. Multiple linear regression models were built providing 
understanding of the impact of filler and binder properties on granule and tablet quality attributes (i.e. 16 
DoE responses). The impact of fillers on the granule and tablet responses was more dominant compared 
to the impact of binder type and concentration. The filler properties had a relevant effect on granule 
characteristics, such as particle size, friability and specific surface area. Binder type and concentration 
revealed a relevant influence on granule flowability and friability as well as on the compactability 
(required compression force during tableting to obtain target hardness). In order to evaluate the DoE 
models’ validity, a verification of the DoE models was performed with new formulations (i.e. a new 
combination of filler, binder type and binder concentration) which were initially not included in the 
dataset used to build the DoE models. The combined PCA (principle component analysis)/DoE approach 
allowed to link the excipient properties with the drug product quality attributes.  
1. Introduction 
 
Continuous twin screw wet granulation is a promising alternative to batch wet granulation technologies 
for solid dosage form manufacturing in the pharmaceutical industries due to its potential for an 
accelerated development process with a lean scale up and savings in drug substance [1]. Considering the 
difference in granulation process, and in particular the shorter granulation time of a continuous wet 
granulation process, compared to high shear wet granulation, the effect of excipients on process 
performance and product quality attributes may not necessarily be transferable. This understanding 
however is of fundamental importance as basis for a quality by design (QbD)-based formulation 
development [2]. A number of studies have been published which investigated different formulations 
processed via twin screw wet granulation in order to study the influence of excipient material attributes 
(e.g. particle size or water binding capacity) on the drug product’s potential critical quality attributes 
(pCQAs) (e.g. granules particle size distribution and tablet tensile strength). Mainly, excipients like lactose 
[3],[4], microcrystalline cellulose [5], dicalcium phosphate, or mixtures thereof were used. Some 
formulations also contained active pharmaceutical ingredients (API), focusing on variation in API particle 
size [5], API hydrophobicity [6] or drug load [7]. For a tabular overview the reader is referred to the review 
of M. Tezyk [8]. By including hydroxypropyl methylcellulose as hydrophilic matrix former in formulations, 
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Vanhoorne et al. and Thomson and O`Donnel showed that controlled release formulations with sustained 
release over 16-20 hours were also processable via continuous twin screw wet granulation [9], [10]. 
However, it remains challenging to compare excipients with very different characteristics in the same 
study since the resulting formulations require e.g. different liquid-to-solid (L/S) ratios in order to obtain 
granules of good quality [11]. Therefore the above-mentioned studies focused on a limited variation in 
formulation composition, hence the obtained scientific conclusions can mainly be considered formulation 
specific.  
For this reason, an important driver for this research work was to include excipients (fillers and binders) 
with different material properties in one experimental design and to systematically study their impact on 
process and product performance of a continuous twin screw wet granulation process. DoE is generally 
limited in the number of factors which can be studied due to limitations in the number of experiments 
that can be performed. Therefore, one of the main challenges was to investigate a broad range of 
excipient properties which might potentially impact the drug product’s pCQAs as factors in the same DoE 
study. As previously described by the authors in [12], principle component analysis (PCA) was used to 
reduce large data sets of excipient characteristics (1 data set for fillers and 1 data set for binders) to a 
limited number of overarching properties (i.e. the principal components). These overarching properties 
explained most of the variability of the original excipient property data sets: 4 principal components (PCs) 
explained 98.4% of the overall variability in the filler data set, while 93.4% of the overall variability in the 
data set of binders was covered via 3 PCs. Moreover, PCA of the filler and binder data set allowed revealing 
similarities and differences in filler and binder characteristics among materials of different chemical 
nature as well as between material grades. PCA also enabled to identify those properties which were 
mainly responsible for these differences and similarities of the excipients. PCA and DoE were combined 
with the intention to understand the influence of excipient (filler and binder) characteristics and 
formulation composition upon granule and tablet attributes after continuous twin screw wet granulation. 
The objective was to develop statistical models which are capable of predicting the pCQAs after 
granulation and tableting for a certain combination of filler and binder as well as to select an optimal 
combination of filler and binder leading to desired drug product characteristics based on the models 
predictions.  
 
Figure 1 depicts the step-wise systematic approach that was followed in this study [13].  The performance 
and results of steps 1-4 were published in [12], while steps 5-8 are presented in this publication. First, 
pharmaceutical fillers and binders suitable for twin screw wet granulation were selected and extensively 
characterized with regard to their physico-chemical properties and solid state characteristics (steps 1 & 
2). PCA was then performed on the resulting data sets of excipient properties (1 PCA on filler data set and 
1 PCA on binder data set) in order to identify the overarching properties, i.e. PCs (steps 3 & 4). Using these 
overarching properties as DoE factors, suitable combinations of fillers and binders can be selected based 
on an experimental design (step 5). In this study two commonly used low viscosity grade binders were 
selected. The resulting statistical DoE models were used to understand and predict the impact of the 
overarching excipient properties on granule and tablet quality attributes. In addition, the process 
performance of the selected formulations was evaluated (steps 6-8).  
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Figure 1. Stepwise overview of the systematic approach to generate formulation understanding 
2. Material and Methods 
 
 
Microcrystalline cellulose (Avicel PH101, Avicel PH105, Avicel PH301, FMC Biopolymer, Philadelphia, USA), 
α-lactose monohydrate (Pharmatose 200M, Pharmatose 350M, DFE Pharma, Goch, Germany and 
GranuLac 200, Meggle Group, Wasserburg, Germany) and mannitol (Parteck M200, Parteck Delta M, 
Merck, Darmstadt, Germany) were used as fillers. Hydroxypropyl methylcellulose (Pharmacoat 603, Shin 
Etsu, Tokyo, Japan) and polyvinylpyrrolidone (Kollidon K30, BASF, Ludwigshafen, Germany) were used as 
binders in this study. Croscarmellose sodium (Disolcel GF, Mingtai Chemical Co, Taoyuan Hsien, Taiwan), 
magnesium stearate (Mallinckrodt, St. Louis, USA) and colloidal silicon dioxide (Aerosil 200, Evonik, 
Rheinfelden, Germany) were used to prepare the final blend for tablet compression. 
 
 
2.2.1. Identification of filler and binder types 
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The intention in this study was to investigate formulations which consisted of one filler and one binder. 
The selection of fillers included commonly used types suitable for wet granulation with differences in 
chemical nature (e.g. lactose, MCC, mannitol) and properties, such as water solubility or compression 
behavior (brittle/plastic). Further variability in excipient characteristics was obtained by selecting filler 
grades differing in particle size (e.g. Pharmatose 200M vs. Pharmatose 350M) and density (e.g. Avicel 
PH101 vs. Avicel PH301). The 8 selected fillers were extensively characterized as described in a previous 
paper [12]. Using PCA, the overarching properties of the filler data set were identified.  
Kollidon K30 (PVP) and Pharmacoat 603 (HPMC) were selected as commonly used and low viscosity binder 
grades for wet granulation.  
2.2.2. Selection of binder concentration 
The binder concentration range for the DoE was defined at 1-2% (in the dry granules) based on the 
outcome of preliminary trials (data not presented). Due to the short granulation time, the binders were 
added as aqueous dispersions. The pre-trials revealed that the maximum binder concentration which 
could be added in the granule formulation was limited. First, the binder solubility in the aqueous 
dispersions is limited. Secondly, there is a limitation in pumpability and control of constant liquid flow for 
highly concentrated, highly viscous binder dispersions depending on the applied set-up of tubing and 
pumps (see section 2.3.1). Due to the limited water uptake capacity of pure lactose, this formulation was 
considered as the worst case for wet granulation, as it requires a low water content for granulation. For 
this lactose formulation, a binder concentration in the formulation of maximum 2% could be reached for 
both binder types. Although 2% binder concentration is well below the maximal concentration for HPMC 
and PVP recommended by the suppliers (i.e. 2-5%), the pre-trials showed that a binder concentration 
range of 1-2% resulted in pronounced differences in granule properties (e.g. granule PSD and granule 
friability). Hence, the selected concentration range was considered sufficiently discriminating. 
Furthermore, with a concentration range of 1-2% a controlled and reproducible pumpability was ensured.     
2.2.3. Factors of the DoE 
5 factors were studied in the experimental design. 3 factors were the score values of the 3 principal 
components (PC) derived from the PCA of the fillers data set which consisted of the fillers’ physico-
chemical and solid state properties [12]. These 3 PCs together defined the filler type in the formulation 
where PC1 represented the moisture-related, PC2 the flow-related and PC3 the density/particle size-
related filler properties. In that way, three overarching filler properties were investigated in the DoE, while 
all underlying filler characteristics were indirectly included in the experimental design.The fourth 
qualitative factor defined the binder type (PVP or HPMC). The fifth factor represented the binder 
concentration in the dry granules varying between 1 and 2%. The binder types were not represented by 
their PCA score values in the experimental design and thus not selected by their overarching properties 
as this approach leads to the selection of high viscosity grade binders which had limitations regarding 
pumpability during processing (data not presented). 
2.2.4. Statistical design 
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Based on these 5 factors, a d-optimal interaction design was selected (MODDE, Version 11.0, Umetrics®, 
Umeå, Sweden) resulting in 27 experiments including 3 center point experiments (see Table 1).  
D-optimal designs are used when a non-standard experimental design needs to be created (e.g. irregular 
experimental regions, multi-level qualitative factors or a combination of process and mixture factors). In 
this design, the constraints resulted from the fact that only specific combinations of factors 1, 2 and 3 (i.e. 
specific combinations of score values) could be selected since these factors represent the overarching 
filler properties which could not be chosen arbitrarily. Figure 2 demonstrates how the numerical values 
of the DoE factors (which are the score values of the principal components) were derived from the PCA 
scores plot. As shown for Pharmatose 350M as an example, every filler type has specific values for the 
principal components which results in a fixed combination of DoE factors 1, 2 and 3. A perfect 
orthogonality, e.g. by combination of score value 1 for factor 1 (PC 1), score value 0 for factor 2 (PC 2) and 
score value 1 for factor 3 (PC 3) is not possible since this combination does not correspond to a filler. 
 
Figure 2. 3-dimensional PCA scores plot of the fillers. Each filler is located in this space according to its overarching properties 
(PC1, PC2 and PC3). Pharmatose 350M is highlighted as an example. Its t1, t2 and t3 are the score values to be used as DoE 
factor values for Pharmatose 350M. 
 
By applying the selected d-optimal design, the experiments were defined in a way that the factor ranges 
were maximally covered [13]. The asset of this d-optimal design was that the factors 1, 2 and 3 (which 
represent the fillers score values of the overarching properties) enabled to link the DoE with the original 
Page 10 of 36 
 
filler PCA model and underlying filler data set in order to understand the impact of filler properties upon 
the pCQAs of granules and tablets, being responses of the DOE (see further). A limitation of the selected 
design was that confounding partially occurred between 2-factor interaction terms as well as between 
main factor and 2-factor interaction terms. However, no confounding above the default threshold of 0.3 
was present between the main model terms [14]. Confounding of factors can be attributed to a deviation 
from perfect orthogonality of the factors and impedes the assignment of an observed effect to one of the 
confounded factors. The DOE responses which were selected for the statistical model are described in 
detail in section 2.4.  
2.2.5. Experimental runs 
Table 1 provides an overview of the experiments. The center point was run in triplicate (experiment 
number 19-21).  
Table 1. DoE design matrix 
Experiment 
number  
(not run 
order) 
Filler type 
Binder type 
(factor 4) 
Binder 
concentration 
in granules 
(factor 5) 
Filler  
principal 
component 1  
(factor 1) 
Filler  
principal 
component 2  
(factor 2) 
Filler  
principal 
component 3  
(factor 3) 
1 Avicel PH301 Kollidon 1.5% -3.37 -0.70 0.98 
2 Avicel PH105 Pharmacoat 1.5% -3.84 1.14 -0.30 
3 Avicel PH301 Pharmacoat 2.0% -3.37 -0.70 0.98 
4 Avicel PH301 Kollidon 1.0% -3.37 -0.70 0.98 
5 Parteck M200 Pharmacoat 1.0% 1.83 -5.56 -1.18 
6 Avicel PH105 Pharmacoat 2.0% -3.84 1.14 -0.30 
7 Avicel PH105 Kollidon 1.0% -3.84 1.14 -0.30 
8 Granulac 200 Pharmacoat 1.0% 2.20 1.71 0.21 
9 Avicel PH101 Kollidon 2.0% -4.31 -0.14 0.02 
10 Parteck M200 Pharmacoat 2.0% 1.83 -5.56 -1.18 
11 Parteck M200 Kollidon 1.0% 1.83 -5.56 -1.18 
12 Parteck Delta M Pharmacoat 2.0% 2.76 -0.28 2.18 
13 Parteck Delta M Kollidon 1.0% 2.76 -0.28 2.18 
14 Pharmatose 200M Kollidon 1.0% 2.94 1.51 1.09 
15 Pharmatose 350M Pharmacoat 1.0% 1.77 2.31 -3.00 
16 Pharmatose 350M Pharmacoat 2.0% 1.77 2.31 -3.00 
17 Pharmatose 350M Kollidon 1.0% 1.77 2.31 -3.00 
18 Pharmatose 350M Kollidon 2.0% 1.77 2.31 -3.00 
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19 Avicel PH301 Pharmacoat 1.5% -3.37 -0.70 0.98 
20 Avicel PH301 Pharmacoat 1.5% -3.37 -0.70 0.98 
21 Avicel PH301 Pharmacoat 1.5% -3.37 -0.70 0.98 
22 Avicel PH101 Pharmacoat 1.0% -4.31 -0.14 0.02 
23 Parteck Delta M Pharmacoat 1.0% 2.76 -0.28 2.18 
24 Granulac 200 Kollidon 2.0% 2.20 1.71 0.21 
25 Parteck Delta M Kollidon 2.0% 2.76 -0.28 2.18 
26 Parteck M200 Kollidon 2.0% 1.83 -5.56 -1.18 
27 Pharmatose 200M Pharmacoat 2.0% 2.94 1.51 1.09 
 
The DoE batches were manufactured via continuous twin screw wet granulation followed by fluid bed 
drying (using a six-segmented fluid bed dryer). The tablet compression of the dried granulate was 
performed in batch mode after addition of the extra-granular phase. Granules and tablets were 
characterized via IPC tests. Figure 3 provides an overview of the process flow, including the IPC tests 
that were performed for granules and tablets.  
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Figure 3. Process flow chart for the manufacturing of DoE batches including IPC tests 
 
2.3.1. Granulation  
The ConsiGma®-25 technology (GEA Pharma Systems, Collette®, Wommelgem, Belgium) was used for the 
manufacturing of the granules. This technology consisted of a twin screw granulator linked to a six-
segmented fluid bed dryer and a granule conditioning unit with a cone mill [15].   
Process parameters setting for granulation 
Since the objective of this study was to understand the influence of the formulation composition on the 
product and process performance it was important to minimize the influence of process variables as well 
as of raw material variability on granule quality. Therefore, the same lots of excipients were used 
throughout the DoE study. Also the process parameters were set to the same fixed values wherever 
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possible. Granulation was conducted at a granulation jacket temperature of 25 °C. The temperature of 
the inlet air in the fluid bed dryer was set to 50 °C. For dry milling of the granules a sieve size of 1.575 mm 
and a rotating speed of 1000 rpm was used. For all experiments a screw configuration of 2x6 kneading 
elements in an angle of 60° was used, while a block of 6 kneading elements was positioned after each 
liquid entry port in the granulation barrel (Figure 4). Binder liquid was added via the first and water via 
the second entry port of the barrel. Although the viscous binder liquid and water were separately added 
during granulation, the miscibility of both phases in the granulation barrel was visually confirmed during 
pre-trials with coloured binder liquid (data not shown).  
 
Figure 4. Scheme of the position of the liquid addition ports and kneading elements in the granulation barrel 
Other granulation parameters, however, were adjusted due to variations in formulation composition in 
order to avoid under- or over-granulation and to obtain a proper product. Especially the water content 
needed for wet granulation varied depending on the filler type in the formulation. A systematic approach 
for the selection of the most appropriate settings was applied for the parameters “water content” and 
“screw speed” in order to ensure optimal granulation conditions for each formulation:  prior to the 
manufacturing of a batch, first, the appropriate water content and secondly, the optimal screw speed was 
identified. For the identification of the appropriate water content, granules were produced at a fixed 
screw speed setting and granule samples were collected at different water contents, starting from very 
dry and powdery granules and increasing the water content stepwise until granules were over-wetted. 
The collected granule samples were visually examined with regard to particle size and examined by hand 
regarding their state of agglomeration and binding. The binder liquid feeding system (Figure 5) was set-
up to ensure consistent binder concentration in the formulation as it was possible to adjust the water flow 
rate independently of the granulation liquid flow rate. Once the most appropriate setting for “water 
content” was identified, in a next step the screw speed was adjusted accordingly to optimize the granule 
particle size, where needed. The decision on acceptable granule size was taken based on operator 
experience and the objective was to achieve comparable wet granule sizes for all manufactured batches. 
Powder mass feed rate and binder liquid feed rate were selected to reach the target binder concentration 
in the formulation. The ratio of powder feed rate over screw speed was kept constant at 0.02 (e.g. 10 kg/h 
powder mass flow over 500 rpm screw speed) for all batches to achieve a consistent barrel filling degree. 
Table 2 provides an overview of the applied granulation process parameters L/S ratio, throughput filler 
and screw speed per batch.   
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Table 2. Applied process parameters per batch during granulation 
Experiment 
number 
Filler type Binder type 
Binder 
concentration 
in granules 
L/S ratio 
throughput 
filler (kg/h) 
screw speed  
(rpm) 
1 Avicel PH301 Kollidon 1.5% 0.43 10 500 
2 Avicel PH105 Pharmacoat 1.5% 0.90 10 500 
3 Avicel PH301 Pharmacoat 2.0% 0.49 11 500 
4 Avicel PH301 Kollidon 1.0% 0.45 13 600 
5 Parteck M200 Pharmacoat 1.0% 0.21 13 600 
6 Avicel PH105 Pharmacoat 2.0% 0.79 11 500 
7 Avicel PH105 Kollidon 1.0% 0.75 13 600 
8 Granulac 200 Pharmacoat 1.0% 0.10 13 600 
9 Avicel PH101 Kollidon 2.0% 0.59 11 500 
10 Parteck M200 Pharmacoat 2.0% 0.20 11 500 
11 Parteck M200 Kollidon 1.0% 0.21 13 600 
12 Parteck Delta M Pharmacoat 2.0% 0.11 11 500 
13 Parteck Delta M Kollidon 1.0% 0.10 13 600 
14 Pharmatose 200M Kollidon 1.0% 0.07 13 600 
15 Pharmatose 350M Pharmacoat 1.0% 0.10 13 600 
16 Pharmatose 350M Pharmacoat 2.0% 0.07 11 500 
17 Pharmatose 350M Kollidon 1.0% 0.08 13 600 
18 Pharmatose 350M Kollidon 2.0% 0.08 11 500 
19 Avicel PH301 Pharmacoat 1.5% 0.48 10 500 
20 Avicel PH301 Pharmacoat 1.5% 0.50 10 500 
21 Avicel PH301 Pharmacoat 1.5% 0.50 10 500 
22 Avicel PH101 Pharmacoat 1.0% 0.84 13 600 
23 Parteck Delta M Pharmacoat 1.0% 0.11 13 600 
24 Granulac 200 Kollidon 2.0% 0.06 11 500 
25 Parteck Delta M Kollidon 2.0% 0.10 11 500 
26 Parteck M200 Kollidon 2.0% 0.18 11 500 
27 Pharmatose 200M Pharmacoat 2.0% 0.09 11 500 
28 Avicel PH101 Kollidon 1.0% 0.67 13 600 
29 Avicel PH101 Pharmacoat 2.0% 0.55 11 500 
30 Parteck M200 Pharmacoat 1.5% 0.19 10 500 
31 Pharmatose 350M Pharmacoat 1.5% 0.09 10 500 
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The drying time in the fluid bed dryer was adjusted to reach a target LOD (loss on drying) of the granules 
which corresponded to the original LOD of the filler in the formulation. This approach was used in order 
to obtain a residual moisture in the granules which is in equilibrium at ambient conditions. The target LOD 
was defined as 0.5-1.0% for lactose and mannitol and 3.0-4.0% for microcrystalline cellulose. The inlet 
airflow was adjusted to ensure optimal fluidization conditions to account for the varying weight of 
granules depending on the water content that was used for granulation. The binder liquid was fed to the 
granulation barrel using peristaltic pumps. Tubings with inner diameters varying from 1.6 to 6.4 mm were 
selected as appropriate for the water and binder liquid addition in order to reach the target feed rate. 
Nozzles with diameters of 0.8 to 2.4 mm were applied to guarantee a constant liquid flow at the target 
liquid feed rate.  
 
Figure 5. Scheme for set-up of binder liquid and water addition 
  
Binder Liquid Water
Mass Flow 
Meter
Pump 1 Pump 2 Pump 3
Mass Flow 
Meter
Granulation Barrel
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2.3.2. Final blend preparation 
Extragranular phase was added to the granules prior to tablet compression. 0.5% silicon dioxide, 1.5% 
croscarmellose sodium and 1.0% magnesium stearate were selected as extragranular excipients for all 
DoE batches. Silicon dioxide was added to provide sufficient flowability to the blend, magnesium 
stearate was selected as most common lubricant to ensure smooth tablet compression and prevent 
sticking. Croscarmellose sodium was added for adequate tablet disintegration. A croscarmellose 
concentration of 1.5% was selected in order not to overrule the effects of the formulation composition 
on disintegration time and secondly, obtain disintegration times which were in a realistic range 
according to pharmacopoeial requirements. Silicon dioxide and croscarmellose sodium were sieved (1.0 
mm mesh size) and mixed with the milled granules in a tumble blender (Turbula T10B, Willy A. 
Bachofen, Muttenz, Switzerland) at 24 rpm for 5 minutes. Magnesium stearate was sieved (1.0 mm 
mesh size), added to the blend and further mixed for 3 minutes.  
2.3.3. Tablet compression  
Tablet compression parameters were fixed for all batches in order to minimize their influence on the 
tablet characteristics. Tablets were compressed using a rotary press (Korsch XL200, Berlin, Germany) 
which was equipped with 4 pairs of 9 mm flat-faced punches running at 30 rpm. Tablets with a mass of 
300 mg were compressed at forces of 8, 15 and 22 kN. In addition, tablets with a target hardness of 75 N 
were compressed for each batch in order to allow comparison of tablet attributes at a standardized 
hardness.  
2.3.4. Characterization of granule attributes 
Samples of the produced granules were collected per batch and characterized by the test methods 
described below.  
Particle Size Distribution 
The particle size of granules was analysed using sieve analysis. Sieves of 1400, 1000, 710, 500, 355, 250, 
180, 125 and 90 μm were used. A motion amplitude of 2mm (continuous mode) was applied for 5 
minutes. The sample size was 100 g. The median particle size D63.2 in µm was calculated based on mass 
according to the Weibull distribution. Moreover the fine fraction was calculated as % of granules below 
125 µm, the yield fraction as % of granules between 125 and 710 µm, and the coarse fraction as % of 
granules above 710 µm.  
Bulk and tapped density 
The volume of 100 g granules after 0 taps (volumebulk) and 1250 taps (volumetapped) was determined 
using a tapping machine (J. Engelsmann, Ludwigshafen a. Rhein, Germany). Considering the sample 
mass, bulk density (mass/volumebulk in g/ml ) and tapped density (mass/volumetapped  in g/ml) were 
calculated as well as the Hausner Ratio (densitytapped/densitybulk) [16]. 
Flowability 
Flowability of granules was characterized by means of ring shear testing (Ring Shear Tester RST-XS, Dr. 
Dietmar Schulze, Wolfenbüttel, Germany) applying a pre-shear of 1000 Pa. The three most suitable 
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normal loads were chosen automatically for each measurement by the device, whereas the first normal 
load was repeated as a fourth normal load measurement point. The flow function coefficient (ffc), which 
is the ratio of consolidation stress to unconfined yield strength, was calculated [17].  
Moisture content 
A halogen moisture analyser (Mettler Toledo HR83, Mettler-Toledo, Greifensee, Switzerland) was used 
to measure loss on drying (LOD) (n=1, in %) at a drying temperature of 90°C until the weight variation 
was below 2 mg within 30 sec.  
Specific Surface Area (BET method) 
In the validity range of the BET-isotherm, the specific surface area (in m2/g) was measured by means of 
nitrogen adsorption (Tristar II 3020, Micrometrics, Norcross, USA) (n=2). Prior to measurements, the 
samples were over-night degased at vacuum. 
Friability 
The friability of granules was measured using a friability tester (PTF E Pharma Test, Hainburg, Germany) 
as described by Vercruysse et al. [18]. The fine fraction of the granules was removed prior to the 
measurements using a 250 μm sieve. Afterwards 10.0 g of the granules (Iwt) were filled into the drum 
together with 200 glass beads of 4 mm diameter. At a speed of 25 rpm a 10 minute run was performed. 
The generated granule size fraction below 250 μm was again removed and the residual amount of 
granules was weighed (Fwt). The friability was calculated as ((Iwt - Fwt)/Iwt) * 100 in %. 
 
2.3.5. Characterization of tablet attributes  
Tablet mass, height, diameter and hardness were measured for 8, 15 and 22 kN compression forces as 
well as for the samples with a target hardness of 75 N. Additionally, disintegration time and abrasion 
were determined for tablets with 75 N target hardness. 
Tablet hardness and solid fraction 
Tablet thickness, diameter, weight and hardness were determined for a sample of 10 tablets processed 
at each compression force as well as the 75 N hardness samples with an automatic tablet testing system 
(Sotax HT 100, Sotax, Aesch, Switzerland). Tablet solid fraction was calculated from tablet mass (m in g), 
volume (V in cm3) and true density (ρtrue in g/cm3) as (m/V)/ρtrue. True density of the final blend before 
compression was measured using a helium pycnometer (AccuPyc 1330, Micrometrics, Norcross, USA). 
Five purges at 19.5 psig and five runs at 19.5 psig were conducted in one measurement (n=2).  
Abrasion 
100 g of de-dusted tablets (m1 in g) with target hardness of 75 N were filled into a Weis-Fogh drum 
(Friabilator AE-1, Biomation, Jugenheim, Germany) which rotated 1250 times at a speed of 100 rpm. 
After the stress test, tablets were de-dusted again, the remaining tablet weight was determined (m2 in g) 
and abrasion (in %) was calculated as ((m1-m2)/ m1)*100. 
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Disintegration 
The disintegration time (in sec) of the 75 N target hardness tablets (n=6) was determined using a 
disintegration tester (basket method; Sotax DT2, Sotax AG, Aesch, Switzerland) with automatic endpoint 
detection. Demineralized water with a temperature of 37°C was used as disintegration medium. 
Compression force 
The compression force (in kN) which was needed to reach a target tablet hardness of 75N was recorded 
and used as an indirect measure for tablet hardness.    
 
 
The above-described granule and tablet attributes were used as DoE responses (see Table 3).   
Table 3. List of granule and tablet model responses 
Granule responses Tablet responses 
Bulk density Disintegration time 
Tapped density Tablet abrasion 
Hausner ratio Solid fraction of tablets with 75 N hardness 
Particle size D63.2 Compression force needed to reach 75 N target tablet hardness 
Fine fraction  <125 µm Ejection force at 15 kN compression force 
Yield fraction 125-710 µm  
Coarse fraction 710-1400 µm   
Flowability   
Friability   
Specific surface area   
Torque granulation barrel   
 
Multiple linear regression (MLR) models were fitted for each response using Modde (Version 11.0, 
Umetrics®, Umeå, Sweden). Responses were thus studied independently from each other. A logarithmic 
transformation of responses was performed if needed in order to convert a non-normal into a normal 
distribution since the latter is a general requirement for linear regression [14]. Orthogonally scaled and 
centred variables were used in the coefficient plots to achieve comparability of factors. 
The models were fitted and optimized for two purposes. First, the models were fitted with main model 
terms in order to understand which factors (i.e. the formulation properties) influence the responses (i.e. 
granule and tablet properties) (see section 3.3.1). Although the statistical design allowed the inclusion of 
interaction model terms, it was not beneficial for this purpose to include interaction model terms due to 
confounding among the main and interaction model terms. Second, the models were fitted for prediction 
and model verification purpose. Here the addition of interaction model terms can be beneficial to improve 
the model fit. The models were optimized by removing statistically insignificant model terms as long as 
this resulted in larger Q2 values [6] (results see sections 3.2 and 3.4). As specific parameters (i.e. inlet air 
flow in the fluid bed dryer, LOD of dry granules and inlet air humidity in the fluid bed dryer) introduced 
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uncontrolled variability during the experiments, these parameters were added to the DoE as uncontrolled 
factors (one uncontrolled factor at a time).   
3. Results and Discussion 
 
 
A total of 31 formulations (27 DoE batches plus 4 batches for external model verification purpose, see 
Table 1 and Table 7) were manufactured via continuous wet granulation in this study.  
Typically formulations designed for wet granulation processes consist of a blend of multiple fillers (e.g. 
two complementary fillers like MCC and lactose). In this study, however, formulations in their most simple 
form were used with the objective to obtain more pronounced effects of the different filler types on the 
product characteristics. For the majority of batches, no manufacturing issues were observed as 
appropriate granules and tablets could be produced. During wet granulation, limitations were observed 
when processing formulations with Avicel PH301 as filler. Although these formulations yielded granules, 
the granulator had to be restarted several times as the process was automatically interrupted when the 
maximum screw torque was exceeded. This observation might be attributed to the higher density of Avicel 
PH301 compared to the two other Avicel grades since the density is the property which is different for 
Avicel PH301 compared to Avicel PH105 and PH101. This observation is in contrast to the expectation that 
the higher density of Avicel PH301 results in a lower filling degree of the granulation barrel which might 
result in a reduced screw torque. Potentially, despite the differences in the overall barrel filling degree for 
the Avicel grades according to their different densities, comparable filling levels might be achieved in the 
kneading element area: At the kneading elements (where most friction occurs) the smallest space is 
available between screw elements and granulation barrel wall which would result in equal amounts of 
powder for all grades regardless of the powder density. When the space around the kneading elements is 
fully filled with wetted powder, this would results in a higher mass of Avicel PH301 (due to higher density 
of Avicel PH301 of 0.433 g/ml compared to Avicel PH101 of 0.308g/ml and Avicel PH105 of 0.313g/ml) 
which potentially results in higher resistance and friction in the kneading element area and thus in higher 
screw torque.  
As expected, it was more difficult to obtain a stable and consistent granulation liquid flow with increasing 
viscosity of the binder liquid. Particularly binder solutions with a high viscosity (e.g. for formulations with 
2% HPMC binder concentration) required a suitable selection of tubing size and assessment of appropriate 
pump speed with pre-trials in order to ensure a consistent flow at the target binder liquid flow rate. 
Although the majority of batches showed a reasonable to good tablet compression performance (maximal 
observed ejection force of approx. 360 N), some formulations were limited in the process performance 
during tablet compression.  For batch 15 (Pharmatose 350M + 1% Pharmacoat) and batch 31 (Pharmatose 
350M + 1.5% Pharmacoat; one of the model verification batches, see section 3.4) high ejection forces (up 
to 1600 N) were observed. Batch 31 did not allow to compress tablets at 15 kN compression force or 
higher since tablets broke during ejection from the die. However, batches with Pharmatose 350M + 2% 
Pharmacoat or with Kollidon (at any concentration) could be processed into tablets without difficulties. 
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Some formulations revealed sticking tendencies (Batch 5, 10, 15, 17) or showed lamination at 22 kN 
compression force (batch 2, 6, 7). The three latter formulations for which lamination was observed at 
22kN, contained Avicel PH105 as filler. Although MCC undergoes plastic deformation during compression, 
it was assumed that the high compression force of 22 kN at a tablet weight of 300 mg resulted in over-
compression. Over compression (i.e. excessive compaction pressure) during tabletting causes a flattening 
out of granules which reduces the bonding-ability due to flat granule surfaces without irregularities [19]. 
Therefore, the compacts tend to laminate. Avicel PH105 is designed as the most compressible MCC quality 
among the grades included in this study. Hence, the state of over-compression is expected to be reached 
at lower compression forces compared to the other MCC grades (Avicel PH101 and PH301) [20].  
 
An overview of the model parameters R2 and Q2 after model optimization is given in Figure 6.  
 
Figure 6. Summary of fit: R2 (green bars) and Q2 (blue bars) of the optimized models (the * indicates that the response was log 
transformed)  
R2 is an indicator for the model fit and describes how well the variation in a response can be explained 
by the model terms. The closer the value is to 1, the better the model fit is. Overall the models had a 
good fit (R2) for all responses. However, assessment of model quality should also take Q2 into account 
which indicates the predictive power of the model.  Q2  is defined as 1 − (
𝑃𝑅𝐸𝑆𝑆
𝑆𝑆𝑡𝑜𝑡
) where PRESS is the 
prediction residual sum of squares calculated based on all model samples and SStot is the total sum of 
squares of the responses [14]. A Q2> 0.5 generally indicates that the model has a good predictive power. 
The model predictability is further discussed in section 3.4.  
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For all responses (except for disintegration time) a good reproducibility was obtained since the variation 
of the center point experiments per response was low and much smaller than the overall variability of the 
DoE experiments. An example for a replicate plot is shown in Figure 7. 
 
Figure 7. Replicate plot of the response "Fine fraction" of granules. Replicates are highlighted in blue (number 19, 20 and 21) 
In this study, it was observed that the variation of factors in the defined experimental space resulted in 
relevant variation of the granule and tablet characteristics for the majority of responses (Table 4), which 
was a good foundation to obtain meaningful quality models.  
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Table 4. Numerical values of granule and tablet responses for the DoE runs. (*measurement values are missing) 
Experiment 
number
Filler type Binder type
Binder 
concentration 
in granules
Bulk density 
(in g/ml) 
Tapped 
density
(in g/ml)
Hausner ratio
Particle size 
D63.2
(in µm) 
Fine fraction 
(<125 µm)
(in %)
Yield fraction 
(125-710 µm)
(in %)
Coarse 
fraction (710-
1400 µm)
(in %)
Flowability
(ffc)
Friability
(in %)  
Specific 
surface area
(in m2/g) 
Torque 
granulation 
barrel
(in Nm)
Disintegration 
time
(in sec)
Tablet 
abrasion 
(in %)
Solid fraction 
@75N
Compression 
force @75N
 (in kN)
Ejection force 
@15kN
(in N)
1 Avicel PH301 Kollidon 1.5% 0.57 0.68 1.19 594 14.9 55.6 29.5 4.4 2 0.4 4.7 36 0.4 0.81 7.5 46
2 Avicel PH105 Pharmacoat 1.5% 0.53 0.64 1.21 454 20.9 59.8 19.4 5.4 7 1.0 3.3 24 0.6 0.79 6.5 38
3 Avicel PH301 Pharmacoat 2.0% 0.63 0.75 1.19 587 16.6 53.6 29.9 7.0 3 0.4 11.1 217 0.5 0.89 15.0 44
4 Avicel PH301 Kollidon 1.0% 0.61 0.75 1.23 550 17.7 55.7 26.6 3.6 3 0.5 8.4 169 1.0 0.88 15.0 47
5 Parteck M200 Pharmacoat 1.0% 0.56 0.63 1.13 373 28.1 55.9 15.7 4.0 10 3.3 2.1 93 0.4 0.82 9.5 365
6 Avicel PH105 Pharmacoat 2.0% 0.53 0.68 1.28 366 33.1 51.3 15.7 5.4 6 1.0 3.3 103 0.8 0.80 7.0 43
7 Avicel PH105 Kollidon 1.0% 0.48 0.66 1.38 281 44.1 43.2 12.6 3.5 9 1.0 3.2 88 1.0 0.80 7.0 42
8 Granulac 200 Pharmacoat 1.0% 0.6 0.69 1.15 284 39.2 50.2 10.6 4.3 24 0.5 2.1 97 0.7 0.86 13.0 158
9 Avicel PH101 Kollidon 2.0% 0.45 0.56 1.24 420 31.2 47.3 21.7 10.2 4 1.0 3.6 19 0.8 0.73 5.0 39
10 Parteck M200 Pharmacoat 2.0% 0.55 0.62 1.13 384 26.0 57.7 16.2 4.2 9 3.3 2.0 113 0.2 0.80 8.0 80
11 Parteck M200 Kollidon 1.0% 0.57 0.64 1.12 422 25.2 54.2 20.4 4.1 7 2.9 2.8 119 0.2 0.79 7.0 113
12 Parteck Delta M Pharmacoat 2.0% 0.51 0.65 1.27 360 34.4 50.8 15.0 4.6 8 0.6 1.8 94 0.8 0.82 8.0 168
13 Parteck Delta M Kollidon 1.0% 0.51 0.6 1.18 445 26.0 51.7 22.0 4.3 4 0.8 3.6 114 0.6 0.83 7.0 62
14 Pharmatose 200M Kollidon 1.0% 0.53 0.64 1.21 202 47.2 47.3 5.6 2.8 18 0.2 1.7 106 0.5 0.88 15.0 92
15 Pharmatose 350M Pharmacoat 1.0% 0.55 0.66 1.20 207 48.5 46.9 4.6 2.4 66 0.4 1.4 104 * 0.86 22.0 1378
16 Pharmatose 350M Pharmacoat 2.0% 0.56 0.65 1.16 210 49.2 45.7 5.0 3.7 28 0.4 1.3 161 0.5 0.85 11.0 129
17 Pharmatose 350M Kollidon 1.0% 0.53 0.63 1.19 253 33.4 58.0 8.5 2.8 18 0.3 3.1 104 1.3 0.87 15.0 87
18 Pharmatose 350M Kollidon 2.0% 0.56 0.64 1.14 351 33.9 49.7 16.2 6.4 11 0.4 3.0 160 0.5 0.83 9.0 119
19 Avicel PH301 Pharmacoat 1.5% 0.6 0.71 1.18 556 16.3 56.5 27.2 * 2 0.4 5.7 248 0.5 0.88 14.0 45
20 Avicel PH301 Pharmacoat 1.5% 0.62 0.74 1.19 643 13.9 52.4 33.7 6.0 5 0.4 10.1 210 0.5 0.89 14.0 43
21 Avicel PH301 Pharmacoat 1.5% 0.63 0.74 1.17 553 16.6 57.1 26.3 6.0 3 0.4 8.1 153 0.5 0.88 14.5 46
22 Avicel PH101 Pharmacoat 1.0% 0.52 0.62 1.19 537 19.0 53.5 27.7 3.7 1 1.1 3.4 142 0.6 0.83 10.0 51
23 Parteck Delta M Pharmacoat 1.0% 0.49 0.58 1.18 281 37.7 52.7 9.5 3.4 18 0.7 1.4 99 0.5 0.86 10.5 77
24 Granulac 200 Kollidon 2.0% 0.59 0.71 1.20 294 40.5 45.8 13.6 5.2 15 0.5 1.4 177 0.7 0.82 8.0 176
25 Parteck Delta M Kollidon 2.0% 0.52 0.6 1.15 490 29.2 44.9 25.9 2.2 1 0.5 4.6 161 0.7 0.81 6.5 195
26 Parteck M200 Kollidon 2.0% 0.57 0.65 1.14 421 28.4 51.1 20.4 6.4 5 2.7 3.2 168 0.2 0.76 5.5 176
27 Pharmatose 200M Pharmacoat 2.0% 0.58 0.68 1.17 305 34.6 53.7 11.6 5.1 17 0.3 1.6 266 0.6 0.87 11.5 118
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In order to avoid confounding in the model terms (see above), linear models with main model terms only 
were selected to evaluate if, and to what extent, the studied factors (i.e. fillers overarching properties, 
binder type and concentration) had an impact on the responses (i.e. granule and tablet properties) (see 
section 2.4). The results which are discussed in section 3.3 are based on the main term models. A list of 
the effects per response is given in Table 5.  
Table 5. Overview of main term model effects for untransformed responses (remark: no information on statistical 
significance is provided in this table; for statistical significance of factors see Table 6) 
Response 
Filler PC1  
(factor 1) 
Filler PC2  
(factor 2) 
Filler PC3  
(factor 3) 
Binder type 
(factor 4) 
Binder 
concentration  
(factor 5) 
Bulk density 0.00 -0.01 0.00 -0.02 0.01 
Tapped density -0.01 0.00 0.00 -0.02 0.01 
Hausner ratio -0.02 0.02 0.01 0.02 0.00 
Particle size D63.2 -53.59 -39.72 55.35 12.22 33.34 
Fine fraction (<125) 4.05 3.97 -3.49 0.33 -0.79 
Yield fraction (125-710) -0.69 -1.43 -0.12 -2.74 -1.86 
Coarse fraction (710-1400) -3.41 -2.50 3.65 2.37 2.71 
Flowability -0.51 -0.18 -0.02 0.26 1.96 
Friability 3.83 4.15 -7.05 -8.07 -7.22 
Specific surface area 0.05 -0.67 -0.35 -0.08 -0.06 
Torque granulation barrel -1.08 -0.27 0.81 0.18 0.34 
Disintegration time 5.36 0.89 9.82 -21.95 34.73 
Tablet abrasion -0.02 0.13 -0.01 0.10 -0.11 
Solid fraction @75N 0.00 0.01 0.01 -0.03 -0.03 
Compression force @75N 0.16 1.08 -0.74 -3.02 -3.59 
Ejection force @ 15kN 50.62 22.17 -115.47 -120.96 -118.73 
 
 
3.3.1. Overview: impact of factors on responses 
The coefficient plot (Figure 8) displays the factors’ regression coefficients per response including 95% 
confidence intervals. The coefficients reflect the change in the response when a factor is varied from its 
average setpoint to its high setpoint while keeping the other factors at their center point. The confidence 
intervals indicate whether the coefficients can be considered statistically different from zero. These 
statistically insignificant terms can be removed from the model during model optimization. 
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Figure 8. Coefficient plot for the response specific surface area: Increasing the factors "flow-related properties (PC2)" and 
"dynamic flow (PC3)" resulted in a reduction of granule specific surface area 
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Table 6. Overview of the factor impacts on responses: arrows in green indicate a significant and pharmaceutically relevant 
impact, arrows in black indicate a significant but pharmaceutically not relevant impact (models with main model terms were 
used for this table) 
Response PC1 
(moisture-
related) 
PC2  
(flow-related) 
PC3  
(dynamic flow & 
others) 
Binder 
concentration 
Binder type 
Particle size D63.2    --- --- 
Fine fraction   --- --- --- 
Yield fraction ---  --- --- --- 
Coarse fraction    --- --- 
Bulk density --- --- --- --- --- 
Tapped density --- --- --- --- --- 
Hausner ratio   --- --- --- 
Flowability  --- ---  --- 
Friability    () borderline  
Specific surface 
area 
---    --- --- 
Disintegration 
time 
--- --- --- --- --- 
Tablet abrasion ---  --- --- --- 
Solid fraction 
@75N 
---  --- ---  
Compression force 
@75N 
--- --- ---   
Torque granulation 
barrel 
 --- --- --- --- 
Ejection force @ 
15kN  
---  --- --- 
 
Table 6 summarizes the significance and pharmaceutical relevance of the coefficients of the models (with 
main model terms) for the different responses. The coefficient plots were used to obtain the information 
which is summarized in the table. Overall, the impact of filler properties on the granule and tablet 
responses appear to be more dominant compared to the impact of binder type and concentration. Binder 
type or concentration only revealed a relevant influence on granule flowability (using a higher binder 
concentration improved granule flowability) and friability (using Kollidon as binder reduced granule 
friability) as well as on tablet compression force as an indicator for tabletability (a higher binder 
concentration and Kollidon as binder both resulted in lower compression forces). Among the overarching 
properties of the fillers, the moisture-related properties (1st PC) and the flow-related properties (2nd PC) 
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of the fillers showed a dominant impact on the responses compared to the dynamic flow properties of 
the filler (3rd PC).  
3.3.2. Responses without pharmaceutically relevant impact of fillers and binders 
The influence of some factors proved to be statistically significant on some responses (bulk and tapped 
density, Hausner ratio, yield fraction, torque in the granulation barrel, disintegration time and solid 
fraction). However, the changes in the responses were not considered pharmaceutically relevant (i.e. the 
impact was significant but the observed change was rated too small to be of practical relevance).  
None of the studied factors had a significant influence on the responses bulk and tapped density, 
respectively. Moreover, limited variation within the response range was obtained for bulk density (0.45-
0.63 g/ml) and tapped density (0.56-0.75 g/ml) as well as for solid fraction (0.73-0.89) (Table 4). However, 
as the experimentally observed values of these responses were within common target ranges (e.g. 0.4-
0.7 g/ml for bulk density, 0.6-0.8 g/ml for tapped density and 0.7-0.9 for solid fraction), optimization of 
those responses is therefore not necessary. Since a change in the formulation factors did not influence 
these granule and tablet properties, the advantage is that other responses can be optimized while those 
responses remain within the desired range. Prior to tablet compression, 1.5% of croscarmellose sodium 
was added to the extra granular phase. This disintegrant concentration was considered sufficient for all 
manufactured formulations since the tablet disintegration time was below 5 minutes for all batches. This 
might be the reason why the studied filler and binder properties did not show a significant influence on 
disintegration time. Furthermore, the addition of a disintegrant might have overruled a potential small 
influence by fillers and binders. An efficient way of influencing the disintegration time is expected via 
proper selection of disintegrant type and concentration rather than by varying filler and binder properties.  
The screw torque is a resulting process parameter and can thus be considered as a response in the DoE, 
as it cannot be actively controlled. Especially in view of long runs, a high screw torque might be 
unfavourable. None of the studied formulation properties significantly affect the screw torque. The only 
formulations which had an elevated screw torque during processing contained Avicel PH301 (see Table 
4).  
3.3.3. Factor impact on individual responses 
Granule particle size distribution (PSD) 
The granule PSD is of high relevance for the downstream process performance and the potential critical 
quality attributes of the final drug product. The granule PSD has for example an impact on granule 
flowability and this directly could impact tablet mass and content variation [21], [22]. High fraction of fines 
can also lead to segregation issues during tablet compression, which might result in content uniformity 
issues. Furthermore granule PSD can impact the compressibility of the product as well as dissolution 
performance [23], [24]. Therefore the PSD of the granules is considered as a key response which is often 
in focus during formulation and process design.  
The statistical granule diameter obtained from the Rosin-Rammler distribution function (D63.2) [25] was 
significantly impacted by the three overarching filler properties: by changing the factors PC1 or PC3 from 
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their lowest to highest setpoint, the D63.2 changed by 40-55 µm for each factor. As D63.2 is calculated 
cumulatively, it contains information about the shift in particle size distribution. The models revealed that 
fillers with high PC1 and/or PC2 score values increased the granules fine fraction (by approx. 4% per factor) 
and at the same time decreased the amount of coarse granules (by approx. 3% per factor). Fine and coarse 
fractions were thus anti-correlated.  
Figure 9 is derived from the scores plot of the fillers PCA [12] and was supplemented with information 
from the DoE. It shows that lactose grades yielded smaller D63.2 values, while Avicel PH301 increased 
D63.2. However, changes in D63.2 were probably mainly attributed to changes in the particle size 
distribution. This assumption was based on the finding that yield fraction was not impacted in a relevant 
way (see below), while fine and coarse fraction were impacted by the same factors (PC1, PC2 and PC3) as 
D63.2. Interestingly, no correlation of D63.2 with the filler water uptake behaviour, filler solubility or filler 
particle size D50 was observed (graphs not shown). Therefore, it could be concluded that granule particle 
size was neither affected by the original particle size of the filler nor by its water solubility or water uptake 
behaviour in the selected experimental set-up. It is expected that at a fixed L/S ratio, excipient properties 
like particle size and water uptake revealed an effect on granule particle size. In this study, however, the 
L/S ratio was defined in order to assure effective granulation for each formulation and to avoid over- or 
under-granulation. The differences in L/S ratio might be the reason that the excipient properties did not 
show a relevant impact on granule particle size. No relevant formulation impact was observed on the yield 
fraction: PC2 was the only factor that significantly impacted the yield fraction. However, an 
increase/decrease of 1.5% yield fraction was not considered relevant. Thus, it was assumed that the yield 
fraction can mainly be adjusted by granulation process parameters like screw speed instead of changing 
the formulation parameters.  
 
Figure 9. Adopted scores plot from the filler PCA to visualize how the selection of a filler type will influence granule particle 
size 
Page 28 of 36 
 
Granule flowability 
The filler properties had a negligible influence on granule flowability (effect of max. 0.5 units), while a 
higher binder concentration could improve the flowability (effect of 2.0 units) regardless of the binder 
type that was used. The binder concentration studied in this design ranges from 1-2% and further 
investigation would be needed to understand if the effect is even more pronounced at higher binder 
concentrations.  
Granule friability 
The granule friability was used as indicator for granule strength. Using PVP as binder reduced the granule 
friability (effect of approx. 8%) and a trend was observed that friability decreased when using higher 
binder concentrations (effect of approx. 7%). Since all overarching filler properties impacted the granule 
friability, friability can be substantially lowered by selecting the right filler properties, i.e. a low PC1 and 
PC2 score values in combination with a high PC3 score value. A correlation (R2=0.6) was found between 
the granule fine fraction and friability (Figure 10): friable and therefore weak granules resulted in a higher 
amount of fines.  
 
Figure 10. Correlation plot fine fraction (%) vs. friability of granules (%) 
Tabletability 
The compression force needed to compress tablets to a defined hardness of 75 N was used as an indicator 
for tabletability. The filler factors did not show a relevant impact on the tablet hardness according to the 
model, while the binders had a considerable effect. Using PVP as binder as well as higher binder 
concentrations improved the tabletability, i.e. a lower compression force was needed to reach the target 
tablet hardness (reduction by approx. 3 kN). In order to better understand why the fillers do not have a 
relevant effect on the tabletability, the compression force required to reach target hardness was plotted 
against the filler types, grouped by filler grades (Figure 11).  
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Figure 11. Tabletability (compression force needed to reach target tablet hardness) grouped by filler type. Error bars indicate 
absolute standard deviation values if available. 
Tablets with MCC or mannitol showed a comparable tabletability, while tablets with lactose were inferior 
considering this response. This observation is in good agreement with previous findings and can be 
explained with the deformation characteristics of the materials [26]. Avicel PH301, however, shows a 
significantly lower tabletability compared to other MCC grades, and its tabletability is similar to that of 
the investigated lactose grades. This observation might be linked to the higher bulk density and lower 
specific surface area (i.e. reduced surface available for particle bonding) of Avicel PH301 compared to 
other MCC grades.  
Tablet abrasion 
PC2 (flow-related properties) was the only factor which showed a relevant impact on tablet abrasion: 
using Parteck M200 with a low PC2 score value as filler reduced the tablet abrasion (by 0.12%).  
Uncontrolled factors 
The approach that was used for this study aimed to keep the influence of process parameters on the 
granule and tablet quality attributes as low as possible to avoid that the impact of formulation parameters 
(PC1, PC2, PC3 of fillers, binder type and binder concentration) would be overruled by the impact of the 
process parameters. However, some process parameters needed to be adjusted to account for the 
different formulation properties (see section 2.4), in order to ensure a good processability. Hence, some 
process parameters and IPC test results were added – one by one - as uncontrolled factors to the design 
and their influence upon the studied responses was evaluated. As none of the uncontrolled factors (i.e. 
inlet air flow, inlet air humidity in the fluid bed dryer and LOD of dry granules) had an impact upon the 
studied responses, the results confirmed that the necessary adaptations of the process parameters to 
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account for formulation needs did not significantly influence drug product attributes and that the 
experimental approach taken in this study was valid. 
 
The purpose of external model verification is to investigate the model applicability for granulation and 
tabletting experiments with formulations that were not included in the model but that were processed 
using factor settings within the experimental space. The formulations selected for external model 
verification are listed in Table 7:   
Table 7. Selected formulations for external model verification 
Experiment 
number 
Filler type 
Binder type 
(factor 4) 
Binder 
concentration 
in granules 
(factor 5) 
Filler  
principal 
component 1  
(factor 1) 
Filler  
principal 
component 2  
(factor 2) 
Filler  
principal 
component 3  
(factor 3) 
28 Avicel PH101 Kollidon K30 1.0% -4.31 -0.14 0.02 
29 Avicel PH101 
Pharmacoat 
603 
2.0% -4.31 -0.14 0.02 
30 Parteck M200 
Pharmacoat 
603 
1.5% 1.83 -5.56 -1.18 
31 
Pharmatose 
350M 
Pharmacoat 
603 
1.5% 1.77 2.31 -3.00 
 
As previously described, the models with interaction terms revealed confounding among the factors 
which impedes to understand which factor is responsible for an observed effect. Nevertheless, the models 
can be used for predictions. Based on the factor settings of the 4 verification experiments (Table 7), the 
response values were predicted using the optimized interaction models. These predicted values were 
compared with the observed experimental values which were generated using the granules and tablets 
manufactured in the verification runs (Table 8).  
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Table 8. Observed and predicted values (including confidence intervals) per verification batch (*for batch 31, no tablets with target hardness of 75N could be manufactured as 
tablets broke during ejection at compression forces above 15kN (see 3.1)) 
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In order to evaluate and verify the predictive quality of the models for data that were not included in the 
models, the difference between the predicted values (P) and the observed values (O) was calculated for 
each response for the 4 verification experiments using the following equation: (O – P /O)*100. The spider 
plot in Figure 12 provides an overview of the model verification assessment per response.  
 
Figure 12. Spider plot: comparison of observed and predicted results per response. A higher percentage is indicative of a large 
deviation between observed and predicted values. The average deviation of the four verification runs is plotted. 
The majority of the predictions were in alignment with expectations, indicating that high Q2 model values 
resulted in a low P/O difference. There are some responses, however, where low Q2 values resulted in 
limited differences between observed and predicted values (e.g. Hausner ratio, yield fraction or 
disintegration time), while the opposite was also observed (e.g. specific surface area or ejection force). A 
possible reason that predictions for the response ejection force resulted in a large P/O difference might 
be that parameters which distinctly influenced the ejection forces (such as concentration of lubricant in 
the formulation) were not included as factors in the experimental design and can thus not be explained 
by the model. Despite the limited variations in the response disintegration time (below 5 minutes for all 
samples) in combination with a low reproducibility of the centre points for this response, the P/O 
difference for this response was still acceptable. The low precision in the measurement method of granule 
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flowability might be responsible for the large P/O difference that was observed for flowability. With a low 
Q2 value for the response flowability, the model indicated limited predictive power which was confirmed 
by a high P/O difference. 
Despite these observations discussed above, the models provided good prediction results for granule and 
tablet responses and the external model verification confirmed the applicability of the existing model also 
for formulations which were not included in the statistical design, but composed of material included in 
the excipients PCA (see [12] for further details on the PCA).   
4.  Conclusion  
By combining PCA with DoE, the number of design factors and subsequently the number of 
experimental batches was reduced while a broad experimental space of filler characteristics was 
investigated in the same statistical design. The application of statistical models enabled to link granule 
and tablet characteristics with the overarching properties using DoE and with the underlying excipients 
characteristics using PCA (Figure 13). Thus, a good understanding was generated regarding how 
formulation impact the quality attributes of granules and tablets. The formulation understanding 
presented in this research work, as well as the statistical models can be used to support a lean 
formulation development: for example, excipients with appropriate characteristics can be selected in 
order to compensate for unfavourable API properties and thus the number of required experimental 
runs can be reduced. Furthermore, the predictive power of the model can be used for formulation 
optimization and troubleshooting, by selecting fillers and binders with appropriate properties to 
improve suboptimal granule or tablet characteristics. The scope of this study is limited to binary placebo 
formulations consisting of one filler and one binder type. In order to understand potential non-linear 
effects of filler mixtures on drug product properties, further studies would be required which could 
follow a similar approach. Furthermore, an understanding of the impact of the API properties on the 
drug product pCQAs is also of interest. One approach would be to characterize the API according to the 
applied methods for fillers and update the PCA model by including the API properties. Based on the 
resulting three principle component values for the API, the statistical model should allow qualitative 
predictions of the API effect on the drug product pCQAs.    
 
 
Figure 13. Combined PCA/DoE approach 
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